Research Priorities in CKD: Report of a National Workshop Conducted in Australia by Tong, Allison et al.
Special ReportFrom the
Sydney, Syd
Hospital at
3Crowe Ass
of Health R
ern Territor
plant and R
Nephrology
The George
School of M
andra Hosp
and Ipswic
Brisbane; 12
La Trobe U
Monash Un
vices Resea
Western Au
Am J KidneResearch Priorities in CKD: Report of a National Workshop
Conducted in Australia
Allison Tong, PhD,1,2 Sally Crowe, PG Dip,3 Shingisai Chando, MPH,1,2
Alan Cass, PhD,4 Steve J. Chadban, PhD,5 Jeremy R. Chapman, FRCP,6
Martin Gallagher, PhD,1,7,8 Carmel M. Hawley, MBBS,9,10,11 Sophie Hill, PhD,12
Kirsten Howard, PhD,1 David W. Johnson, PhD,9,10,11 Peter G. Kerr, PhD,13
Anne McKenzie,14 David Parker,13 Vlado Perkovic, PhD,8
Kevan R. Polkinghorne, PhD,12 Carol Pollock, PhD,1,15
Giovanni F.M. Strippoli, PhD,1,16,17,18 Peter Tugwell, FRCP,19
Rowan G. Walker, PhD,20 Angela C. Webster, PhD,1,2,6 Germaine Wong, PhD,1,2,6 and
Jonathan C. Craig, PhD1,2
Research aims to improve health outcomes for patients. However, the setting of research priorities is usually
performed by clinicians, academics, and funders, with little involvement of patients or caregivers and using
processes that lack transparency. A national workshop was convened in Australia to generate and prioritize
research questions in chronic kidney disease (CKD) among diverse stakeholder groups. Patients with CKD
(n5 23), nephrologists/surgeons (n 5 16), nurses (n 5 8), caregivers (n5 7), and allied health professionals
and researchers (n5 4) generated and voted on intervention questions across 4 treatment categories: CKD
stages 1 to 5 (non–dialysis dependent), peritoneal dialysis, hemodialysis, and kidney transplantation. The 5
highest ranking questions (in descending order) were as follows: How effective are lifestyle programs for
preventing deteriorating kidney function in early CKD? What strategies will improve family consent for
deceased donor kidney donation, taking different cultural groups into account? What interventions can improve
long-term post-transplant outcomes? What are effective interventions for post hemodialysis fatigue? How can
we improve and individualize drug therapy to control post-transplant side effects? Priority questions were
focused on prevention, lifestyle, quality of life, and long-term impact. These prioritized research questions can
inform funding agencies, patient/consumer organizations, policy makers, and researchers in developing a
CKD research agenda that is relevant to key stakeholders.
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Tong et altopics are neglected even when a substantial amount
of research is publicly funded.4,6,7
Recently, the lack of partnership among re-
searchers, clinicians, and patients has been recog-
nized in many jurisdictions, and major new initiatives
have been forged to ﬁll the gap.8,9 In the United
States, an important element of recent health care
reform was the formation of the Patient-Centered
Outcomes Research Institute (PCORI), which has
a mission to produce and promote high-integrity
research that is “guided by patients, caregivers, and
the broader healthcare community.”10 In the United
Kingdom, the James Lind Alliance was launched in
2004 to unite patients, caregivers, and health care
providers in prioritizing treatment uncertainties for
research.11
Research prioritization exercises with an explicit
process are uncommon in chronic kidney disease
(CKD), and those that exist often do not engage key
stakeholder groups, including patients and caregivers,
in a partnership approach.12-17 The notable exception is
an exercise completed in Canada that focused on
advanced CKD and dialysis and involved physicians,
allied health professionals, and patients receiving or
nearing dialysis.18 The top 10 priorities arising from
this exercise addressed patient-provider communica-
tion, dialysis modalities, itching, access to trans-
plantation, heart health, dietary restrictions, depression,
and vascular access.
Research priority-setting partnerships provide an
opportunity for equitable involvement of patients,
caregivers, and health care providers, which can
improve the relevance, quality, and implementation of
research.19
NATIONAL PRIORITY-SETTING WORKSHOP
Context
Australia is among the world’s 20 largest econ-
omies, with a gross domestic product of approxi-
mately US $1 trillion. In the Australian health care
system, some services are funded by the govern-
ment and others are funded by private health in-
surance. Medicare is the Australian government’s
universal health insurance scheme and provides free
or subsidized treatment to patients in public hospi-
tals. Costs of dialysis and kidney transplantation
are covered by Medicare. However, patients may
choose to dialyze as a private patient at a private
renal unit that is funded by private health insurance
schemes.
A national priority-setting workshop was convened
on February 7, 2014, to generate and prioritize
research questions in CKD in Australia. The intent of
the workshop was to develop a prioritized research
agenda across the entire spectrum of CKD that is2relevant to all key stakeholders: patients, clinicians,
policy makers, and research funders.
Workshop Participants
Participants were eligible if they were patients with
CKD (CKD stages 1-5, 5D, or 5T), family caregivers,
or health professionals with experience in CKD (ne-
phrologists, surgeons, nurses, allied health pro-
fessionals, and researchers); English speaking; 18
years and older; and able to provide informed consent.
Participants were recruited from 7 Australian states
and territories (New South Wales, Victoria, Queens-
land, Northern Territory, South Australia, Western
Australia, and the Australian Capital Territory).
Patients and family caregivers were selected
through Kidney Health Australia (KHA) and recruit-
ing clinicians using purposive and snowballing (ie,
participants were asked to nominate other participants)
strategies to achieve a range of sociodemographic
(age, sex, employment status, education, culturally and
linguistically diverse populations, and location of
residence) and clinical (CKD stage/modality and
duration of diagnosis) characteristics. KHA and
recruiting clinicians were advised of these criteria.
Health professionals and researchers were purpo-
sively selected to capture diversity across years of
clinical experience, age, sex, practice locations, and
afﬁliations with the following stakeholder organiza-
tions: Australian Kidney Trials Network (AKTN),
Australian Institute of Health and Welfare (AIHW),
AustralianGovernmentDepartment ofHealth,National
Health and Medical Research Council, Australian and
New Zealand Society of Nephrology (ANZSN), The
Transplantation Society of Australia and New Zealand
(TSANZ), Australian and New Zealand Dialysis and
Transplant Registry (ANZDATA), Agency for Clinical
Innovation (ACI), and State Renal Health Clinical
Networks. The workshop was convened in hotel
meeting rooms in central Sydney.
Participants received reimbursement for travel and
accommodations. Recruitment continued until the
maximum of 60 participants was conﬁrmed to attend,
with at least half being patients/caregivers. Workshop
capacity was determined by resource availability
(approximate budget of A$20,000 for direct work-
shop costs excluding personnel salaries), group
manageability, and feasibility. All participants were
asked to complete a declaration of interests and
disclosure form. The University of Sydney ethics
committee approved the study.
Of the 60 individuals conﬁrmed to attend the work-
shop, there were 58 (97%) participants, comprising
23 patients, 16 nephrologists and surgeons, 8 nurses,
7 caregivers, and 4 allied health professionals and
researchers. The number of patients/caregivers who
declined participation or those whom we excluded toAm J Kidney Dis. 2015;-(-):---
Table 2. Characteristics of Participating Health Care
Professionals
Characteristic No. (%)
Female sex 10 (36)
Age category
30-39 y 4 (14)
40-49 y 12 (43)
50-59 y 10 (36)
60-69 y 2 (7)
Role
Nephrologist 14 (50)
Surgeon 1 (4)
Researcher 1 (4)
Dietician 1 (4)
Nurse or nurse coordinator 8 (29)
Psychologist 1 (4)
Social worker 1 (4)
Location of practice, by state
New South Wales 13 (46)
Queensland 5 (18)
Victoria 3 (11)
South Australia 3 (11)
Western Australia 2 (7)
Australia Capital Territory 1 (4)
Northern Territory 1 (4)
Experience in caring for patients with CKD
#10 y 7 (25)
11-20 y 7 (25)
21-30 y 11 (39)
.30 y 3 (11)
Ethnic background
Anglo-Saxon 19 (68)
Chinese 4 (14)
Indian 2 (7)
Russian 2 (7)
Mixed ethnicity 1 (4 )
Note: n 5 28.
Abbreviation: CKD, chronic kidney disease.
Table 1. Characteristics of Participating Patients and
Caregivers
Characteristic No. (%)
Participant type
Patient 23 (77)
Caregiver 7 (23)
Female sex 14 (47)
Age category
20-29 y 2 (7)
30-39 y 6 (20)
40-49 y 6 (20)
50-59 y 2 (7)
60-69 y 11 (37)
70-79 y 3 (10)
Employment status
Full time 9 (31)
Part time 8 (28)
Casual 1 (3)
Retired 7 (24)
Not working 2 (7)
Student 2 (7)
Marital status
Married/defacto 22 (73)
Divorced or separated 1 (3)
Single (living with parents, never
married)
6 (20)
Highest level of education
Grade 10 4 (14)
Grade 12 4 (14)
Nonuniversity qualification (certificate, diploma) 8 (28)
University degree (bachelor, master’s, doctoral
degree)
13 (45)
Location of residence, by state
New South Wales 13 (43)
Victoria 6 (20)
Queensland 4 (13)
South Australia 6 (20)
Australian Capital Territory 1 (3)
Area of residence
Metropolitan/urban 25 (83)
Regional 5 (17)
Current mode of RRTa
None 6 (20)
Hemodialysis 10 (33)
Peritoneal dialysis 4 (13)
Kidney transplantation 9 (30)
Ethnic background
White 21 (70)
Greek 2 (7)
Chinese 1 (3)
Lebanese 1 (3)
Jewish 1 (3)
Italian 1 (3)
Portuguese 1 (3)
Mixed ethnicity 1 (3)
Note: n 5 30.
Abbreviation: RRT, renal replacement therapy.
aOf patients; includes RRT of patients whose caregivers
attended the workshop.
Am J Kidney Dis. 2015;-(-):---
Research Priorities in CKDavoid over-recruitment of demographic/clinical char-
acteristics could not be tracked because we used mul-
tiple recruitment strategies. Eight health professionals
declined participation due to prior commitments. Par-
ticipants were aged 23 to 77 years (overall mean age,
49.7 6 12.0 [SD] years; patients/caregivers, 526 14.7
years; and health care providers, 46 6 11.9 years) and
34 (58.6%) were men. Participant characteristics are
provided in Tables 1 and 2.
Prioritization Process
The prioritization process was adapted from the
James Lind Alliance Priority Setting Partnership
methodology for the consensus workshop,20-24 and the
framework for health research priority setting, from
Viergever et al.25 The process is detailed in Fig 1,
and the facilitator’s Interview Guide is provided in
Table S1 (available as online supplementary material).3
Figure 1. Flowchart of the workshop process. Chronic kidney disease (CKD) categories are non–dialysis-dependent CKD, perito-
neal dialysis (PD), hemodialysis (HD), and transplantation (Tx). Abbreviations: PICO, population, intervention; comparator, outcome;
Q, question. *n5 10 maximum per group. **Based on removing duplication and selecting the top-ranked 10 across both lists.
Tong et alFacilitators were required to have a background in
health (public health, medicine, health economics,
psychology, or epidemiology) and prior experience in
moderating focus groups. They were known to the
investigator team to have the skills required for the
task. All facilitators completed a training session that
covered the workshop objectives, the role and skills
of a facilitator, and how to ensure effective dialogue
and manage difﬁcult behavior.
Workshop Methods
The 1-day workshop had 3 phases.
Phase 1
Participants were divided into 6 facilitated groups of
8 to 10 members. The group composition was mixed
(patients, caregivers, and health professionals) and at
least half of each group comprised patients/caregivers.
One group focused on non–dialysis-dependent stages 1
to 5 CKD, and another group, on peritoneal dialysis
(PD). Two groups each were assigned to the topics of
hemodialysis (HD) and transplantation; the emphasis
on these 2 treatment types was based on participant
preferences submitted prior to the workshop and group4facilitation manageability. The group allocations also
reﬂect the higher proportion of prevalent patients in
Australia who are treated by HD or have received a
kidney transplant.26 One trained facilitator (S.C., A.T.,
G.W., K.H., A.R., and S.H.) and 1 co-facilitator (S.C.,
J.C.C., D.T., C.S.H., A.J., and M.L.) were assigned to
each group. Participants were asked to formulate
questions about interventions and to try to generate
questions following the PICO (population, interven-
tion, comparator, outcomes) framework. Generated
questions were displayed on a board or wall. To vote,
each participant was given 5 stickers to place adjacent
to the research questions she or he thought most
important; choices then were discussed as a group. If
needed, additional stickers were distributed for
tiebreaking.
The top 10 questions for each CKD treatment
category were identiﬁed by tallying votes. For the
categories HD and transplantation, which were
covered by 2 groups, the top 5 questions from each
group were combined to form a top 10 for the cate-
gory. Thus, altogether, 4 sets of 10 questions were
produced. A patient representative from each group
reviewed the questions for clarity.Am J Kidney Dis. 2015;-(-):---
Research Priorities in CKDPhase 2
A copy of the top 10 questions for each CKD
category was provided to each group. All groups
discussed and ranked each question within its
respective category. The top 5–ranked questions in
each category progressed onto the next phase.
Phase 3
The group votes were summed and the aggregate
top 5 questions from each CKD category were
distilled into a list of 20 research questions. These
were presented to all participants in a plenary with
participants invited to comment or request clariﬁca-
tion. Each participant received a printed copy and
individually ranked the top 20 questions from 1 (most
important) to 20 (least important).
Data Analysis
Descriptive statistics were calculated using SPSS
(IBM; version 21). The prioritized list of the top 20
research questions for all participants was generated
by combining scores from the top 20 questions that
were individually ranked by participants and calcu-
lating the mean and standard deviation for each
question. Histograms were generated for each ques-
tion’s scores and revealed that the data were not
normally distributed; therefore, median and inter-
quartile range (IQR) were calculated for each question
to determine rank. Questions were then stratiﬁed by
participant group (patients/caregivers vs health pro-
fessionals/researchers), and Mann-Whitney U test was
conducted to test for differences between groups.
A preliminary report of the research priorities
workshop was sent to all invited participants so they
could provide feedback and comment within a 2-week
time frame. It was also uploaded on the KHA website
to disseminate the ﬁndings.27
Research Priorities
Across all groups, a total of 83 research questions
were generated (Table S2). The top 10 questions
ranked by CKD treatment category are provided in
Box 1. The individual top-20 ranking was completed
by 55 (95%) participants. According to median scores,
the 5 highest ranking questions across CKD treatment
categories were: (1) How effective are lifestyle pro-
grams (diet, exercise, and smoking cessation) for
preventing deteriorating kidney function in patients
with early CKD? (2) What strategies will improve
family consent for potential deceased donor kidney
donation, taking different cultural groups into ac-
count? (3) What interventions (drugs, lifestyle) can
improve long-term post-transplant outcomes? (4)
What are the effective interventions for post-HD fa-
tigue? (5) How can we improve and individualize drugAm J Kidney Dis. 2015;-(-):---therapy to provide better control of side effects in
kidney transplantation?
The priority questions focused on prevention, life-
style, quality of life, and long-term impact. Table 3
shows the differences in median scores, IQR, and
rank between patients/caregivers and health care
providers. The difference in median score and IQR
was statistically signiﬁcant for 1 question (“What
interventions are most effective to reduce inter-
dialytic weight gain?”), which had a median score
of 15 (IQR, 9-18) for patients/caregivers versus 10
(IQR, 5-15) for health care professionals, P 5 0.03).
Six questions had a difference in rank of 5 or more
between patients/caregivers and health care providers.
Two questions were ranked as higher priority by at
least 5 rankings among patient/caregivers: What
strategies will improve donor family consent to
deceased donation taking different cultural groups
into account? Are electronic and social media an
effective modality to deliver health promotion about
CKD in the general population? Four questions were
ranked as higher priority among health care pro-
fessionals: What are the effective interventions for
post-HD fatigue? What are the best interventions to
improve the decision-making process of people faced
with HD and to improve their satisfaction and reduce
complications? What kinds of exercise programs are
safe and most effective for PD patients? What in-
terventions are most effective to reduce interdialytic
weight gain?
Of the questions ranked in the top 10 by both
patients and caregivers, 8 appeared in the overall top
10 questions. Of the questions ranked in the lowest
10 by both patients and caregivers, 7 were in the
overall 10 lowest ranked questions. The questions
ranked in the top 7 by patients/caregivers and by
health care professionals were included in the
overall top 10 research priorities. Both groups
ranked the research question “How can technology
be used to improve patient self-monitoring in PD?”
last, which was consistent with the rank of the
combined group.
DISCUSSION
An Australian priority-setting partnership involving
patients, caregivers, policy makers, clinicians, and re-
searchers was convened in February 2014 to elicit
shared research priorities for CKD. Priorities were
focused on prevention, lifestyle, quality of life, and
long-term impact of disease and treatment. For stages 1
to 5 CKD (non–dialysis dependent), the prioritized
questions were centered on lifestyle interventions to
prevent disease progression, education to improve self-
management and access to services, health promotion
in the general community, and referral and support
services to improve quality of life. For PD, the5
Box 1. Top 10 Ranked Research Priorities by CKD Category
Chronic Kidney Disease
1. How effective are lifestyle programs (diet, exercise and smoking cessation) for preventing deterioration in kidney function in
patients with early CKD?
2. Does provision of culturally appropriate information about early CKD modify acknowledgement, medication adherence and
health service uptake in patients with early CKD?
3. Does active implementation of clinical practice guidelines in general practice improve kidney health in patients with early CKD?
4. Are electronic and social media effective for delivering health promotion about CKD in the general population?
5. Do interventions that increase knowledge of support services and early referral practices increase quality of life in patients and
caregivers?
6. Do interventions that enhance self-management in early CKD patients modify health services use and quality of life?
7. Do interventions that enhance shared decision making and planning impact on the quality of RRT in patients with early CKD?
8. Are interventions to enhance education about early CKD detection effective in improving early diagnosis?
9. Are complementary medicines (eg, zinc, iron, vitamin D) effective in preventing progression of kidney disease in patients with
early CKD?
10. Does enhancing acknowledgement of CKD improve kidney health in patients newly diagnosed with early CKD?
Peritoneal Dialysis
1. What is the best diet or nutritional intervention to improve general outcomes of PD patients?
2. How can technology be used to improve patients’ self-monitoring?
3. How can we provide better support for patients/families in transition of care from children to adults?
4. How we can be best provide support services/tools to be integrated to patients/caregivers/families to improve mental health?
5. What is the optimum staff/patient ratio in PD clinics to reduce morbidity?
6. How can we best deliver staff education services to reduce patient complications?
7. What kinds of exercise program are safe and most effective for PD patients?
8. Are there interventions or tools to improve patient cognition and slow decline?
9. How can peer support be integrated to improve patient mental health?
10. What is the best way to provide counseling to improve patient self-esteem?
Hemodialysis
1. What is the impact of polypharmacy on quality of life; what is the best way to make tablet regimes simpler?
2. What are the best interventions to improve the decision making process of people faced with HD and to improve their
satisfaction and reduce complications?
3. What is the benefit of and what is the best planned nutritional program (plus best ‘easy aids’ to help gauge potassium) for better
outcomes (improving lean body mass/muscle)?
4. What are the effective interventions for post HD fatigue?
5. What strategies reduce anxiety?
6. What strategies help patients maintain work while on HD?
7. What are the best characteristics to identify which elderly patients will benefit from HD?
8. Can a potassium indicator (discrete, measurable) be developed to deal with potassium fluctuation and self-manage better?
9. What interventions are most effective to reduce inter-dialytic weight gain in patients with HD?
10. Does implementing a personalized care plan increase quality of life for patients on HD and caregivers?
Transplantation
1. What strategies will improve donor family consent to deceased donation, taking different cultural groups into account?
2. What interventions (drugs, lifestyle) can improve long term post-transplant outcomes?
3. What psychological interventions would improve the psychological health for transition between stages of kidney disease?
4. How do we improve health outcomes in young transplant recipients?
5. What can we do to improve/individualize drug therapy in terms of better management of side effects?
6. Can implementing a pharmacy clinic positively influence compliance and stop transitioning back to dialysis?
7. What additional psychological and medical support would be beneficial post donation for live donation?
8. Determining extended criteria for elderly donor recipient pairs (donors over 65 years)?
9. What counseling services would help children of parents going through the transplant process?
10. In those with a failing graft would restarting dialysis earlier improve psychological well-being and health?
Abbreviations: CKD, chronic kidney disease; HD, hemodialysis; PD, peritoneal dialysis; RRT, renal replacement therapy.
Tong et alquestions addressed diet and nutrition, self-monitoring
technology, transition, integrated services to improve
mental health, and educational interventions for staff to
reduce complications. The prioritized questions for
HD related to managing polypharmacy, shared deci-
sion making, nutritional management, fatigue and anxi-
ety, and interdialytic weight gain. For transplantation,6prioritized questions focused on interventions to improve
posttransplantation outcomes, increasing donation rates,
individualized therapy to manage side effects, and psy-
chological interventions.
Overall, there was broad consensus between pa-
tients/caregivers and health professionals. This may
be explained in part by the balanced mix of patients/Am J Kidney Dis. 2015;-(-):---
Table 3. Top 20 Research Priorities Across All CKD Categories
Rank Questiona
Overallb
Median [IQR]
Patients and
Caregiversc
Health Care
Professionals
Mann-
Whitney U
Median
[IQR] Rank
Median
[IQR] Rank U P d
1 How effective are lifestyle programs (diet, exercise and
smoking cessation) for preventing deterioration in
kidney function in patients with early CKD?
5 [2-10] 6 [4-10] 4 4 [2-9] 1 261.5 0.1
2 What strategies will improve donor family consent to
deceased donation, taking different cultural groups into
account?
6 [3-13] 5 [2-11] 1 9 [6-13] 6 262.5 0.1
3 What interventions (drugs, lifestyle) can improve long
term post-transplant outcomes?
7 [2-11] 5 [2-11] 1 8 [3-11] 4 314.0 0.5
4 What are the effective interventions for post HD fatigue? 7 [4-14] 10 [4-14] 8 6 [4-13] 2 300.5 0.4
5 What can we do to improve and individualize drug therapy
in terms of better management of side effects in kidney
transplantation?
8 [4-12] 5 [3-11] 3 10 [5-15] 7 245.0 0.01
6 What strategies help patients maintain work while on HD? 8 [4-13] 9 [6-14] 7 6 [4-9] 3 243.5 0.06
7 What psychological interventions would improve the
psychological health for transition between kidney
stages?
9 [5-16] 8 [5-13] 6 11 [5-17] 10 277.5 0.2
8 How do we improve health outcomes in young transplant
recipients?
10 [5-15] 8 [4-14] 5 11 [5-16] 9 305.0 0.4
9 What are the best interventions to improve the decision
making process of people faced with HD?
10 [6-16] 11 [7-16] 13 8 [4-15] 5 269.0 0.1
10 Does provision of culturally appropriate information about
early CKD modify acknowledgement, medication
adherence, and health service uptake in patients with
early CKD?
11 [6-15] 12 [7-16] 15 11 [7-15] 12 324.5 0.6
11 Do interventions that increase knowledge of support
services and early referral practices increase quality of
life in patients and caregivers?
11 [6-16] 10 [5-14] 9 11 [8-15] 13 309.5 0.5
12 How can we best provide support services to patients,
carers, and families to improve mental health in PD?
11 [7-16] 11 [5-16] 10 12 [7-15] 14 341.0 0.9
13 Does active implementation of clinical practice guidelines
in general practice improve kidney health in patients
with early CKD?
12 [5-15] 11 [5-17] 11 12 [7-15] 14 343.0 0.9
14 What is the best diet and nutrition to improve general
health outcomes for PD patients?
12 [6-18] 12 [8-15] 17 12 [9-16] 16 334.0 0.8
15 Are electronic and social media an effective modality to
deliver health promotion about CKD in the general
population?
12 [9-16] 11 [6-19] 12 14 [9-17] 19 323.0 0.6
16 How can we best deliver staff education to reduce patient
complications in PD?
13 [6-16] 12 [8-14] 16 14 [8-18] 18 282.0 0.2
17 What kinds of exercise programs are safe and most
effective for PD patients?
13 [8-17] 15 [10-17] 19 11 [6-15] 11 247.0 0.06
18 Does implementing a personalized care plan increase
quality of life of HD for patients and caregivers?
13 [9-17] 12 [6-15] 14 13 [7-16] 17 309.0 0.5
19 What interventions are most effective to reduce inter-
dialytic weight gain?
13 [8-17] 15 [9-18] 18 10 [5-15] 7 230.5 0.03e
20 How can technology be used to improve patient self-
monitoring in PD?
18 [12-20] 17 [12-20] 20 18 [13-20] 20 347.5 0.9
Abbreviations: CKD, chronic kidney disease; HD, hemodialysis; IQR, interquartile range; PD, peritoneal dialysis.
aTotal n5 55; 2 participants did not disclose their identity but their rankings are included in the median calculation.
bn 5 27.
cn5 26.
dP 5 Asymptotic significance (P) value.
eSignificant at P, 0.05.
Research Priorities in CKDcaregiver and health professionals in each breakout
discussion group. Also, the nominal group technique
allows all participants to contribute ideas (research
questions) individually and to discuss these ideas as aAm J Kidney Dis. 2015;-(-):---group. We sought a process of hearing views equally
and all groups were moderated by a trained facilitator
who encouraged open and collaborative dialogue
among all participants.7
Tong et alSome questions were noticeable by their absence.
There was a lack of discussion about mortality,
although it may have been implicit in some of the
generic outcomes identiﬁed. Most researchers would
regard mortality as an important outcome and chal-
lenge in CKD and many clinical studies are focused
on mortality, especially in dialysis. The apparent
absence of mortality in research priorities has also
been observed in other areas of medicine, including
cancer, mental health, and pulmonary disease, for
which patients/caregivers emphasize living with and
managing the illness rather than dying from it.5,28,29
We speculate that this may also reﬂect a perception
that mortality may not be a realistic outcome, partic-
ularly in dialysis, given that mortality rates remain
unacceptably high despite advances in dialysis tech-
nologies and pharmacology.30-32
Comparison With Other Research Priority-Setting
Initiatives
Some of the research priorities generated in this
workshop reﬂect priority areas that are consistent with
ﬁndings from a recent systematic review of research
priority-setting activities in kidney disease.1 These
included prevention of CKD progression, dietary
management, access to transplantation, patient edu-
cation, and psychosocial impact of CKD.
Recently, the US National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) commis-
sioned the Kidney Research National Dialogue to ask
practitioners, clinical and basic scientists, and mem-
bers of advocacy and professional groups to identify
high-priority research objectives for CKD.16 The
research objectives covered prevention, prognosis,
treatment, and outcomes. Diet and nutrition and
transition from pediatric to adult care were the only
priorities that were similar to those identiﬁed in our
study. The US Agency for Healthcare Research and
Quality (AHRQ) also sought to identify topics for
systematic reviews of primary research that compared
the effectiveness of strategies to prevent, detect, and
treat CKD or its complications.13 Stakeholder partic-
ipants were physicians and members of health pro-
fessional societies, health insurance organizations, the
government, and patient advocacy groups (patients
and caregivers were not involved). Among the 18
highest ranked priorities for funded comparative
effectiveness systematic reviews in CKD, approxi-
mately one-quarter appear to align with the top
research questions in our workshop. These priorities
were access to health care, patient knowledge and
education, computer decision support for CKD man-
agement, and dietary strategies to slow CKD pro-
gression. The variation in priorities may be due
largely to the priority-setting approach used, whether
categories and topics were identiﬁed a priori by the8investigator team, and whether patients and caregivers
were excluded.
Recently Manns et al18 conducted a national survey
and consensus workshop with patients, caregivers,
and health professionals to identify research priorities
for patients receiving dialysis or nearing dialysis-
dependent CKD. Among the top 10 research prior-
ities they identiﬁed, a number were similar to those
identiﬁed in our workshop; these questions concerned
improving self-management in patients with CKD,
shared decision making, quality of life, increasing
access to kidney transplantation, reducing the psy-
chosocial impact of CKD, dietary strategies, depres-
sion and anxiety, and caregiver support.
Strengths and Potential Limitations
This national priority-setting partnership workshop
followed a systematic and transparent process of
engaging patients, caregivers, clinicians, researchers,
and policy makers in generating and prioritizing
research questions across the spectrum of CKD. This
was a large-scale priority-setting workshop, which has
contributed to innovative methodological develop-
ment through use of concurrent facilitated discussion
groups and a 3-phase process with real-time data
analysis to distill the number of questions to be ranked
in each subsequent phase. We have demonstrated that
this approach is effective in allowing participants to
identify and prioritize research questions.
However, there are several potential limitations.
While the purposive sampling strategy captured a
range of demographic and clinical characteristics,
culturally and linguistically diverse patients/care-
givers were relatively under-represented (n 5 8/30
[27%]). Additionally, no participants identiﬁed as
indigenous Australian (although some participants
advocated for speciﬁc indigenous issues) or resided in
remote areas. Also, 45% of patients/caregivers were
university graduates, which may not be reﬂective of
the CKD population. The extent to which the prior-
ities address all relevant Australian stakeholders may
be limited. Differences in research priorities by de-
mographics could not be determined because the
workshop was designed to develop consensus and not
powered to detect differences attributed to de-
mographic characteristics.
We recognize that individuals were self-selecting
and inevitably may promote a personal or institu-
tional perspective. However, this was to some extent
mitigated by achieving maximum possible variation
in demographic and clinical characteristics and by
recruiting health professionals from different in-
stitutions. Further, having trained facilitators moder-
ate the discussion helped ensure that participants
contributed ideas in a respectful manner and across a
wide range of perspectives.Am J Kidney Dis. 2015;-(-):---
Research Priorities in CKDThe questions formulated did not always fulﬁll the
PICO criteria; thus, they need to be reﬁned further for
study by trials or systematic reviews. We also did not
exclude questions that existing research may have
already answered, and therefore the resulting prior-
ities may not be indicative of uncertainties about
CKD treatment. Previous priority-setting partnerships
following the James Lind Alliance approach con-
ducted preliminary surveys and voting exercises to
identify and prioritize treatment uncertainties,
removed questions that had been addressed by exist-
ing evidence, and conducted a face-to-face workshop
to prioritize the remaining questions.20,24,33,34 How-
ever, we chose to omit these initial steps to ascertain
whether patients/caregivers and health professionals
could identify research questions and priorities
together from the outset. We have shown that it is
possible to compress the research priority-setting
partnership process, which has implications for cost,
resources, and feasibility.
It is unknown whether a 1-day priority-setting
workshop is better at generating decisions that truly
reﬂect the interests of patients and their caregivers
than a workshop preceded by a prolonged participant
engagement process. Nonetheless, the 1-day work-
shop is a frequently used and widely accepted
approach for research priority-setting partnerships and
bears some similarities to the consensus development
conferences outlined in the James Lind Alliance re-
view of priority-setting approaches.35 It is also un-
clear how a methodology based on quantitative
analysis of the number of times questions are sug-
gested and/or voted for compares to a qualitative
analysis of research priorities based on in-depth
engagement with patients and their caregivers. Gath-
ering questions from different routes (eg, group dis-
cussions) can yield very similar questions compared
to a more quantitative survey approach and may give
a more nuanced result in terms of the quality of the
question. However, we are not aware of a purely
qualitative approach that can move from engagement
to priority setting.
Implications for Future Research Priority-Setting
Initiatives
The questions generated in our study were explic-
itly focused on interventions for the treatment and
management of CKD. Nonetheless, the procedure
used could be broadly applied in other research pri-
ority setting exercises. We suggest that prioritization
could be conducted for other types of research ques-
tions that address etiology, diagnosis, and prognosis
or even for exploring the hidden burden of living with
disease. Furthermore, there are aspects of living with
a serious chronic condition that are relevant regardless
of condition (eg, self-managing medicines or broadlyAm J Kidney Dis. 2015;-(-):---based health promotion).36 For example, kidney dis-
ease in children, and conservative management for
stage 5 CKD were beyond the scope of our study and
could be considered for future prioritization initia-
tives. Also, it would be of interest to determine how
well the 5 research priorities identiﬁed by the 2002
US NIDDK Task Force of Health Professionals
(calcium and phosphorus metabolism abnormalities,
neurocognitive and developmental outcomes, pre-
dictors of progression of structural kidney disease/
congenital abnormalities, genetic and molecular risk
factors for CKD and their effects on outcomes, and
the effect of socioeconomic factors on outcomes37)
align with those of patients and caregivers.
Different strategies or approaches to research pri-
ority setting may be required for hard-to-reach com-
munities, including indigenous Australians, who may
have understandings of health, disease, and health
care that differ from the conventional vision of
Western medicine.38-41 Relevant, effective, and
culturally respectful approaches require a mutually
respectful partnership framework, ongoing relation-
ships and engagement, capacity building and active
involvement of indigenous staff, an understanding of
communities’ past and present experiences of
research, recognition of the diversity of indigenous
populations, and support for community ownership.42
The prioritized research questions generated in our
study still need to be mapped against published and
ongoing research to identify questions that address
uncertainties in existing evidence. Also, questions
may undergo further reﬁnement and distillation ac-
cording to the PICO criteria and their feasibility, after
which they can be used to inform the development of
a CKD research agenda that is important and relevant
to key stakeholders, particularly patients and care-
givers. Forums to formulate research agendas (such as
this workshop) will drive clinically oriented research
to answer questions of immediate relevance. Thus, a
different forum may be better suited for priority
setting in discovery-driven research.
Translation of Research Priorities
A key challenge after collaborative research prior-
ity setting is translating shared priorities into the
agendas of funders and researchers. Therefore, eval-
uating the outcomes and impact of priority setting is
critical. The ﬁndings of this study will be used to
inform the research projects selected by the national
peak consumer organization for kidney disease, KHA.
The priorities also will be considered by the AKTN in
planning and designing trials and by the Cochrane
Renal Group in ensuring that systematic reviews
address topics of concern to patients.
It has been proposed that success is achieved in
research priority setting when there is improved9
Tong et alstakeholder understanding and conﬁdence in the
research prioritization process, a shift in priorities or
reallocated resources, heightened decision-making
quality in terms of the appropriate use of evidence,
stakeholder acceptance and satisfaction (or “buy in”),
and provision of information accessible for use or
emulation by others.43 To draw these points out
further, success could be “measured” at several
stages: when research proposals from the research
community are aligned with (or reference) the prior-
itization at the time funding is being sought, when
funding decisions display a resource bias to such
aligned proposals, and when results from funded
proposals are used as an input to subsequent priori-
tization reﬁnements. Ultimately, an increase in the
amount of research that reﬂects the shared priorities of
health professionals and patients/caregivers who live
with CKD would also constitute success.
CONCLUSION
Priority-setting partnerships provide an opportunity
for participative democratic approaches to research
question generation44 and for wide stakeholder
engagement to explore and identify research prior-
ities. Prioritized research questions can inform pa-
tient/consumer organizations, researchers, policy
makers, and funding agencies in developing a shared
CKD research agenda that is relevant to all
stakeholders.
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